BeOne’s gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844